In conclusion, both in vitro and in vivo experiments indicate that pharmaceutical enhancement of eIF2α/ATF4-mediated adaptive stress response by either Gbz or Sephin1 effectively mitigates AVIC and valvular calcification, offering a promising therapeutic strategy against the development of CAVD. The gene discussed is ATF4; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.